Cardiometabolic & kidneyCohort study
Steatotic liver disease as a risk enhancer in the presence of metabolic syndrome
- Population-based cohort study
Authors' conclusion
This study reveals that the significant association between SLD subtypes and mortality risk is mediated by MetS.
Study context
- Population
- NHANES III participants, stratified by metabolic syndrome (MetS) status (International Diabetes Federation criteria)3,521 deaths
- Participants
- 9,217 participants
- Exposure
- Steatotic liver disease (SLD) subtypes vs no SLD, stratified by MetS
- Outcome
- All-cause and cause-specific mortality
- Follow-up
- Median 26.4 years
Main finding
As reported in the abstract
All-cause mortality, with MetS
Hazard ratio (95% CI)
SLD with MetS vs Healthy controlsadjusted
1.56(1.38–1.75)
MASLD vs Healthy controlswith MetS
1.52(1.34–1.72)
MetALD vs Healthy controlswith MetS
1.92(1.41–2.62)
ALD vs Healthy controlswith MetS
2.80(1.56–5.05)
Observational data: associations, not effects.
Further findings
Cause-specific mortality, with MetS
- Increased mortality with MASLD, MetALD and ALD vs no SLD primarily driven by cancer- and diabetes-related mortality; not observed without MetS
Original publication
Steatotic liver disease as a risk enhancer in the presence of metabolic syndrome. Eur J Prev Cardiol. Published 12 June 2025. doi:10.1093/eurjpc/zwaf330
Summarised from the published abstract; every number is checked against it